[Changes in hemostasis during epilespy treatment using dipropyl acetate. Extended study].
The influence of Dipropyl-Acetate (DPA, Ergenyl) on hemostasis parameters was examined in 12 patients. In 8 cases there was a prolongation of bleeding time, in 2 cases thrombocytopenia, in 6 out of 10 cases the platelet adhesiveness was pathologically reduced. We therefore recommend hemostasis-examinations--with emphasis on the thrombocytic system--in patients taking DPA.
D000293:Adolescent; D001772:Blood Cell Count; D001792:Blood Platelets / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D004827:Epilepsy / Q000150:complications / Q000188:drug therapy*; D005164:Factor IX; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D008297:Male; D009392:Nephrectomy; D010973:Platelet Adhesiveness / Q000187:drug effects; D011183:Postoperative Complications; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors; D014631:Valerates / Q000494:pharmacology*; D014635:Valproic Acid / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use
D014631:Valerates; D014635:Valproic Acid; D005164:Factor IX
Veränderungen der Hämostase bei Epilepsie-Behandlung mit Dipropylessigsäure. Erweiterte Untersuchung